Upregulation of GZMK, TREM2, and OR4D10 as Prognostic Biomarkers in Thyroid Cancer: A Pan-Cancer and TCGA Data Analysis

The study of gene anomalies linked to thyroid cancer is gaining more and more attention, and these molecular indicators can offer scholarly support for thyroid cancer diagnosis, therapy selection, and prognosis. Genotype-tissue expression pan-cancer data and The Cancer Genome Atlas (TCGA) were used to investigate the expression of <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i>. In order to assess the relationship between <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i> expression and patient outcome, TCGA clinical survival data were used. We used the clusterProfiler R software tool to conduct enrichment analysis of <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i>. Moreover, TCGA database analysis was used to assess the relationship between immune cell infiltration and <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i> expression. <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i> were strongly expressed in several kinds of malignancies including thyroid cancer. Gene sets related to proliferation that are involved in leukocyte cell-cell adhesion and mononuclear cell differentiation were significantly correlated with high expression of <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i>. Additional investigation revealed a correlation between high T cell and DC (dendritic cell) infiltration scores and high expression of <i>GZMK</i>, <i>TREM2</i>, and <i>OR4D10</i>. According to our research, <i>OR4D10</i>, <i>TREM2</i>, and <i>GZMK</i> could all be genes associated with thyroid cancer.